378 related articles for article (PubMed ID: 33179277)
1. Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations on the use of sodium-glucose cotransporter inhibitors with insulin for treatment of type 1 diabetes (Updated October 2020).
Dashora U; Patel DC; Gregory R; Winocour P; Dhatariya K; Rowles S; Macklin A; Rayman G; Nagi D;
Diabet Med; 2021 Feb; 38(2):e14458. PubMed ID: 33179277
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
Boeder S; Edelman SV
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):62-77. PubMed ID: 31081593
[TBL] [Abstract][Full Text] [Related]
3. SGLT inhibition: a possible adjunctive treatment for type 1 diabetes.
Akturk HK; Rewers A; Garg SK
Curr Opin Endocrinol Diabetes Obes; 2018 Aug; 25(4):246-250. PubMed ID: 29794497
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol.
Goldenberg RM; Gilbert JD; Hramiak IM; Woo VC; Zinman B
Diabetes Obes Metab; 2019 Oct; 21(10):2192-2202. PubMed ID: 31183975
[TBL] [Abstract][Full Text] [Related]
5. Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 1 Diabetes Mellitus.
Li N; Chen R; Liu K
Clin Drug Investig; 2020 Nov; 40(11):991-1000. PubMed ID: 32725362
[TBL] [Abstract][Full Text] [Related]
6. Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data.
Patel K; Carbone A
Ann Pharmacother; 2019 Dec; 53(12):1227-1237. PubMed ID: 31226886
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
Musso G; Gambino R; Cassader M; Paschetta E
BMJ; 2019 Apr; 365():l1328. PubMed ID: 30967375
[TBL] [Abstract][Full Text] [Related]
8. Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus.
El Hage L; Kashyap SR; Rao P
J Prim Care Community Health; 2019; 10():2150132719895188. PubMed ID: 31894715
[No Abstract] [Full Text] [Related]
9. Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: A case report.
Lee IH; Ahn DJ
Medicine (Baltimore); 2020 May; 99(21):e20228. PubMed ID: 32481295
[TBL] [Abstract][Full Text] [Related]
10. NICE guidance on dapagliflozin with insulin for type 1 diabetes.
Adler AI; Ting S; Dent R; Latimer N
Lancet Diabetes Endocrinol; 2019 Oct; 7(10):750-751. PubMed ID: 31488391
[No Abstract] [Full Text] [Related]
11. SGLT inhibitor adjunct therapy in type 1 diabetes.
McCrimmon RJ; Henry RR
Diabetologia; 2018 Oct; 61(10):2126-2133. PubMed ID: 30132030
[TBL] [Abstract][Full Text] [Related]
12. SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature.
Patoulias D; Imprialos K; Stavropoulos K; Athyros V; Doumas M
Curr Clin Pharmacol; 2018; 13(4):261-272. PubMed ID: 30084335
[TBL] [Abstract][Full Text] [Related]
13. Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis.
Hampp C; Swain RS; Horgan C; Dee E; Qiang Y; Dutcher SK; Petrone A; Chen Tilney R; Maro JC; Panozzo CA
Diabetes Care; 2020 Jan; 43(1):90-97. PubMed ID: 31601640
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m
Danne T; Edelman S; Frias JP; Ampudia-Blasco FJ; Banks P; Jiang W; Davies MJ; Sawhney S
Diabetes Obes Metab; 2021 Mar; 23(3):854-860. PubMed ID: 33289297
[TBL] [Abstract][Full Text] [Related]
15. Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis.
Kim YJ; Hwang SD; Lim S
Front Endocrinol (Lausanne); 2020; 11():553. PubMed ID: 32973680
[TBL] [Abstract][Full Text] [Related]
16. Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus.
Sims H; Smith KH; Bramlage P; Minguet J
Diabet Med; 2018 Aug; 35(8):1037-1048. PubMed ID: 29637608
[TBL] [Abstract][Full Text] [Related]
17. Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems-A Literature Review.
Elian V; Popovici V; Karampelas O; Pircalabioru GG; Radulian G; Musat M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396657
[TBL] [Abstract][Full Text] [Related]
18. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes.
Herring RA; Shojaee-Moradie F; Garesse R; Stevenage M; Jackson N; Fielding BA; Mendis A; Johnsen S; Umpleby AM; Davies M; Russell-Jones DL
Diabetes Care; 2020 Sep; 43(9):2128-2136. PubMed ID: 32641376
[TBL] [Abstract][Full Text] [Related]
19. [Life-threatening ketoacidosis in a 25-year-old woman treated with sodium-glucose cotransporter 2 inhibitor].
Lindberg MJ; Kristensen FB; Yildiz A
Ugeskr Laeger; 2016 Nov; 178(47):. PubMed ID: 27908315
[TBL] [Abstract][Full Text] [Related]
20. Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes (January 2021).
Dashora U; Gregory R; Winocour P; Dhatariya K; Rowles S; Macklin A; Rayman G; Nagi D; Whitehead K; Beba H; De P; Patel DC;
Clin Med (Lond); 2021 May; 21(3):204-210. PubMed ID: 34001571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
